Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, Oct. 24 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507... Read More

Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, Oct. 24 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More

Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, Oct. 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More

Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy Versus Physician’s Choice of Chemotherapy in Participants With B7-H4-selected Advanced/Metastatic Endometrial Cancer Who Progressed on or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, Oct. 24 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More

UPPRPB declares final scores for 41,424 Home Guard posts

LUCKNOW, Oct. 24 -- The Uttar Pradesh Police Recruitment and Promotion Board (UPPRPB) declared the final scores of Home Guards' recruitment candidates on its website, on Saturday. The move comes nearl... Read More

India condemns attack on church in Jordan's Karak; reaffirms zero tolerance for terrorism

New Delhi, Oct. 24 -- India has strongly condemned the deadly attack on a church in Karak, Jordan, on Friday, which claimed seven lives and left 34 others injured In an official statement released by... Read More

They doff their hats to Ladbone, By Kunle Ajibade

Nigeria, Oct. 24 -- This book, Ladbone: A Life in Print, edited by Dapo Olorunyomi, the publisher of Premium Times, is a collection of 85 essays in honour of Oyinlade Bonuola, one of the original and ... Read More

Sajjan Singh Yadav appointed Jammu and Kashmir chief secretary

India, Oct. 24 -- The Union government has appointed senior IAS officer Sajjan Singh Yadav as the new chief secretary of Jammu and Kashmir, according to an order issued by the Ministry of Home Affairs... Read More

Running Ahead

Srinagar, Oct. 24 -- With the third edition of the Kashmir Marathon just a day away, Srinagar is gearing up to welcome runners from across the country and abroad. The inauguration of the three-day exp... Read More

Clinical Trial: Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07891286) titled 'Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Ado... Read More

• ««
• «
• 355
• 356
• 357
• 358
• 359
• 360
• 361
• 362
• 363
• 364
• »
• »»